These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11524712)

  • 1. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
    Zhao X; Drlica K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S147-56. PubMed ID: 11524712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
    Zhao X; Drlica K
    J Infect Dis; 2002 Feb; 185(4):561-5. PubMed ID: 11865411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.
    Zhou J; Dong Y; Zhao X; Lee S; Amin A; Ramaswamy S; Domagala J; Musser JM; Drlica K
    J Infect Dis; 2000 Aug; 182(2):517-25. PubMed ID: 10915083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mutant selection window and antimicrobial resistance.
    Drlica K
    J Antimicrob Chemother; 2003 Jul; 52(1):11-7. PubMed ID: 12805267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
    Cebríán L; Rodríguez JC; Escribiano I; Royo SG
    APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant selection window hypothesis updated.
    Drlica K; Zhao X
    Clin Infect Dis; 2007 Mar; 44(5):681-8. PubMed ID: 17278059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options in an era of decreasing antimicrobial susceptibility.
    Drlica K; Schmitz FJ
    J Chemother; 2002 Feb; 14 Suppl 2():5-12. PubMed ID: 12003139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
    Blondeau JM
    Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing face of antibiotic prescribing: the mutant selection window.
    Epstein BJ; Gums JG; Drlica K
    Ann Pharmacother; 2004 Oct; 38(10):1675-82. PubMed ID: 15340128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP; Hankins CD
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure.
    Yan M; Sahin O; Lin J; Zhang Q
    J Antimicrob Chemother; 2006 Dec; 58(6):1154-9. PubMed ID: 17023497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and spread of antibiotic resistance following exposure to antibiotics.
    Cantón R; Morosini MI
    FEMS Microbiol Rev; 2011 Sep; 35(5):977-91. PubMed ID: 21722146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.
    Ferran A; Dupouy V; Toutain PL; Bousquet-Mélou A
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4163-6. PubMed ID: 17709467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.